WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 150 fonti internazionali, con classificazione AI e timeline cluster su singole storie.

Navigazione

Home
Archivio
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Baxfendy approved for uncontrolled hypertension — Warptech Lab News

Baxfendy approved for uncontrolled hypertension

AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase inhibitor approved to treat uncontrolled high blood pressure in people with primary aldosteronism, a hormonal disorder that promotes sodium and water retention, according to a company press release.

lunedì 18 maggio 2026 New tab

490 words~2 min read

May 18, 2026

1 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Other newsrooms on this story

· 10 sources

Full timeline →

medpagetoday.com·May 18, 2026 · 2 g fa
FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients
astrazeneca.com·May 18, 2026 · 2 g fa
Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
morningstar.com·May 18, 2026 · 2 g fa
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
biopharmadive.com·May 18, 2026 · 2 g fa
FDA approves AstraZeneca’s new kind of hypertension drug
fiercepharma.com·May 18, 2026 · 2 g fa
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
endpoints.news·May 18, 2026 · 2 g fa
AstraZeneca's blood pressure pill approved, but competition could be around the corner
statnews.com·May 18, 2026 · 1 g fa
AstraZeneca picks up FDA approval for hypertension drug
morningstar.com·May 19, 2026 · 1 g fa
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
endpoints.news·May 14, 2026 · 6 g fa
AstraZeneca follows Merck with Phase 3 win in bladder cancer
endpoints.news·May 14, 2026 · 6 g fa
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

Related reading

medpagetoday.com

FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives

medpagetoday.com·2 g fa

astrazeneca.com

Baxfendy approved in the US as the first and only aldosterone synthase…

AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the…

astrazeneca.com·2 g fa

morningstar.com

BAXFENDY approved in the US as the first and only aldosterone synthase…

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

morningstar.com·2 g fa

biopharmadive.com

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that…

biopharmadive.com·2 g fa

fiercepharma.com

AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for…

After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI)…

fiercepharma.com·2 g fa

theguardian.com

New drug hailed as ‘gamechanger’ in tackling stubbornly high blood pressure

Trials of baxdrostat have produced ‘exciting’ results for people whose hypertension has proved difficult to control

theguardian.com·8 mesi fa